Stock CRON CRONOS GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Cronos Group Inc. Nasdaq

Equities

CRON

CA22717L1013

Market Closed - Nasdaq
Other stock markets
 21:00:00 09/05/2024 BST 		5-day change 1st Jan Change
2.85 USD +10.47% Intraday chart for Cronos Group Inc. +7.14% +36.36%
05-09 Cronos Shares Jump as Q1 Loss Narrows, Revenue Rises MT
05-09 Cronos Group Up 3.9% in U.S. Premarket Trade as Q1 Loss Narrows on Higher Sales MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 55% by 2026.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CRONOS GROUP INC. Stock Cronos Group Inc.
+36.36% 994M -
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+43.25% 6.3B
B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-15.08% 4.44B
C+
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-6.70% 3.27B
B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+5.47% 3.16B
C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
+0.76% 2.58B -
D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+47.75% 1.96B -
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-5.08% 1.73B - -
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
+2.05% 1.68B - -
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-7.08% 1.63B
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CRON Stock
  4. CRON Stock
  5. Ratings Cronos Group Inc.